CA2303799A1 - Procede d'augmentation du volume osseux - Google Patents

Procede d'augmentation du volume osseux Download PDF

Info

Publication number
CA2303799A1
CA2303799A1 CA002303799A CA2303799A CA2303799A1 CA 2303799 A1 CA2303799 A1 CA 2303799A1 CA 002303799 A CA002303799 A CA 002303799A CA 2303799 A CA2303799 A CA 2303799A CA 2303799 A1 CA2303799 A1 CA 2303799A1
Authority
CA
Canada
Prior art keywords
naturally
occurring
agonist
bone
prostaglandin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002303799A
Other languages
English (en)
Inventor
Mark Walden Lundy
Mitchell Anthony Delong
James Richard Hartke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of CA2303799A1 publication Critical patent/CA2303799A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur de nouveaux procédés d'augmentation du volume osseux, ces procédés consistant à activer les mécanismes ostéoblastiques de la protéine kinase C/du calcium intracellulaire d'un sujet. Cette invention porte également sur un procédé de traitement ou de prévention des maladies osseuses, l'activation se faisant par administration d'un agoniste FP.
CA002303799A 1997-09-09 1998-09-04 Procede d'augmentation du volume osseux Abandoned CA2303799A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5821897P 1997-09-09 1997-09-09
US60/058,218 1997-09-09
PCT/US1998/018337 WO1999012550A1 (fr) 1997-09-09 1998-09-04 Procede d'augmentation du volume osseux

Publications (1)

Publication Number Publication Date
CA2303799A1 true CA2303799A1 (fr) 1999-03-18

Family

ID=22015432

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002303799A Abandoned CA2303799A1 (fr) 1997-09-09 1998-09-04 Procede d'augmentation du volume osseux

Country Status (17)

Country Link
EP (1) EP1035853A1 (fr)
JP (1) JP2001515863A (fr)
CN (1) CN1269720A (fr)
AR (1) AR013478A1 (fr)
AU (1) AU9130298A (fr)
BR (1) BR9811775A (fr)
CA (1) CA2303799A1 (fr)
CO (1) CO5070621A1 (fr)
HU (1) HUP0003584A3 (fr)
ID (1) ID24759A (fr)
IL (1) IL134759A0 (fr)
NO (1) NO20001172L (fr)
PE (1) PE118899A1 (fr)
PL (1) PL339297A1 (fr)
SK (1) SK3402000A3 (fr)
WO (1) WO1999012550A1 (fr)
ZA (1) ZA988229B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE281432T1 (de) 1999-03-05 2004-11-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3607293A (en) * 1992-02-05 1993-09-03 Merck & Co., Inc. Implant therapy for bone growth stimulation
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
AR013478A1 (es) 2000-12-27
WO1999012550A1 (fr) 1999-03-18
ID24759A (id) 2000-08-03
NO20001172L (no) 2000-05-08
ZA988229B (en) 1999-03-09
PL339297A1 (en) 2000-12-04
CN1269720A (zh) 2000-10-11
NO20001172D0 (no) 2000-03-07
EP1035853A1 (fr) 2000-09-20
BR9811775A (pt) 2000-08-29
HUP0003584A3 (en) 2002-12-28
IL134759A0 (en) 2001-04-30
HUP0003584A2 (hu) 2001-02-28
AU9130298A (en) 1999-03-29
PE118899A1 (es) 2000-02-03
JP2001515863A (ja) 2001-09-25
CO5070621A1 (es) 2001-08-28
SK3402000A3 (en) 2000-12-11

Similar Documents

Publication Publication Date Title
US6156799A (en) Method of increasing bone volume using non-naturally-occurring FP selective agonists
US6133230A (en) Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and TGF-β, optionally in combination with IGF-1
US6534534B1 (en) Pharmaceutical composition active in reducing production of MCP-1 protein
DE69635754T2 (de) Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe
JP2002542284A (ja) テトラックの薬学組成物およびその使用方法
CA2303799A1 (fr) Procede d'augmentation du volume osseux
CA2366755A1 (fr) Augmentation du volume osseux par utilisation d'agonistes selectifs d'ep1 n'existant pas naturellement
US9023890B2 (en) Nitrate esters and their use for the treatment of muscle and muscle related diseases
US7238718B2 (en) Method for treating myolytic disease and method for screening antimyolytic agent
WO2000051616A1 (fr) Procede d'accroissement du volume osseux a l'aide de derives de prostaglandine agonisant de maniere selective fp et ep1, non naturels
MXPA00002395A (en) Method of increasing bone volume
JP5039236B1 (ja) 抗不整脈剤及び心房細動抑制剤
DE69928685T2 (de) Heilmittel und/oder vorbeugungsmittel gegen fettleibigkeit
MXPA00002394A (en) Method of increasing bone volume using non-naturally-occurring fp selective agonists
CZ2000808A3 (cs) Použití selektivního FP agonisty, který se přirozeně nevyskytuje
JP2002538122A (ja) 天然に存在しないｆｐ選択的アゴニストおよび骨吸収抑制化合物を用いる骨体積の増加方法
JP5615868B2 (ja) 持続性心房細動モデル及びその製造方法、並びに、心房細動抑制剤のスクリーニング方法
WO2011000562A1 (fr) Eltoprazine pour le traitement de certains troubles du mouvement
Gillespie et al. Department of Physiological Sciences, The U'ntiversity Neucastle utpon Tyne NE2 4HH

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued